Literature DB >> 7927848

Design of dosage regimens: a multiple model stochastic control approach.

D S Bayard1, M H Milman, A Schumitzky.   

Abstract

This paper presents a general stochastic control framework for determining drug dosage regimens where the sample times, dosing times, desired goals, etc., occur at different times and in an asynchronous fashion. In the special case of multiple models with linear dynamics and quadratic cost (MMLQ), it is shown that the optimal open-loop stochastic control with linear control/state constraints can be solved exactly and efficiently as a quadratic program. This provides a simple and flexible method for computing open-loop feedback designs of drug dosage regimens. An implementation of the MMLQ adaptive control approach is demonstrated on a Lidocaine infusion process. For this example, the resulting MMLQ regimen is more effective than the MAP Bayesian regimen at reducing interpatient variability and keeping patients in the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927848     DOI: 10.1016/0020-7101(94)90100-7

Source DB:  PubMed          Journal:  Int J Biomed Comput        ISSN: 0020-7101


  9 in total

1.  A Bayesian approach to tracking patients having changing pharmacokinetic parameters.

Authors:  David S Bayard; Roger W Jelliffe
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

2.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.

Authors:  Michaël Philippe; Michael Neely; Yves Bertrand; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

4.  Fractional calculus in pharmacokinetics.

Authors:  Pantelis Sopasakis; Haralambos Sarimveis; Panos Macheras; Aristides Dokoumetzidis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-10-03       Impact factor: 2.745

Review 5.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

6.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

7.  Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.

Authors:  Michael Neely; Michael Philippe; Teresa Rushing; Xiaowei Fu; Michael van Guilder; David Bayard; Alan Schumitzky; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Ther Drug Monit       Date:  2016-06       Impact factor: 3.681

8.  Achieving target voriconazole concentrations more accurately in children and adolescents.

Authors:  Michael Neely; Ashley Margol; Xiaowei Fu; Michael van Guilder; David Bayard; Alan Schumitzky; Regina Orbach; Siyu Liu; Stan Louie; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

Review 9.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.